RE:RE:RE:RE:RE:RE:RE:RE:I miss all the old school investors from 2018"It's very telling is one of the phrases the shortseller likes to use lol"....really....is that really a phrase that identifies a shortseller......it is more likely that Rosenberg is using his go to reply...."shortseller".....because he cannot come up with anything better....that happens when you lie and mislead investors and then get called out for it.....then he's back to the pump in the very next breath....the Lucid deal.....and the unrealistic comparison with actual successful companies and him tying FSD's success to another company's efforts is another desperate attempt to mislead investors....I've posted this before but let's say ELYM's drug testing turns out great....that success does not tranfer to FSD in any way.....FSD will still have to conduct testing of their own drug compound so essentially restart the testing and trials of FSD 201.....the same drug they just cancelled testing on and wasted millions on......it's a red herring that this pumper is trying to sell you......
DavidRosenberg wrote: It's very telling is one of the phrases the shortseller likes to use lol
listen for now stock price is tanked , waiting for lucid to close so they can rely on more then one drug compound AD mentioned this in the interview as a way to derisk
$ELYM has same drug as FSD, called PEA
Results due first half of 2022 as what they listed on their website if Negative results would be bad for FSD
if they get positive Results maybe will reinforce FSD 201 as a drug , it's dependant on which indication they want to target